Lastly, the GAIA-CLL13 trial randomized young and fit patients with CLL without TP53 aberrations to receive FCR/bendamustine-rituximab, time-limited venetoclax-obinutuzumab, or ibrutinib with venetoclax-obinutuzumab, and found no PFS benefit among patients with mutated IGHV[4]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.